氯喹悖论可能弊大于利，不利于抗击 COVID-19。
Chloroquine paradox may cause more damage than help fight COVID-19.
机构信息
Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, United States of America.
出版信息
Microbes Infect. 2020 May-Jun;22(4-5):154-156. doi: 10.1016/j.micinf.2020.04.004. Epub 2020 Apr 17.
Abstract
Novel coronavirus disease 2019 (COVID-19) pandemic is the most recent health care crisis without specific prophylactic or therapeutic drugs. Antimalarial drug chloroquine (CHL) and its safer derivative hydroxychloroquine (HCHL) have been proposed to be repurposed to treat SARS coronavirus-2 (SARS-CoV-2), the causative agent of COVID-19. CHL/HCHL have anti-inflammatory activity and are used to treat rheumatoid arthritis, osteoarthritis and lupus. Although, CHL/HCHL have an anti-viral activity against several viruses in cell-cultures, the anti-viral activity in-vivo is questionable. Repurposing of CHL/HCHL to treat SARS-CoV-2 infection is appealing. However, there is empirical evidence from animal studies with other viruses suggesting that CHL/HCHL may have an untoward paradoxical effect. One thus cannot exclude the possibility that CHL may increase the severity of the disease and prove deleterious both for the patients and public health efforts to contain the highly contagious and explosive spread of SARS-CoV-2.
摘要
新型冠状病毒病 2019（COVID-19）大流行是最近的一次卫生保健危机，没有特定的预防或治疗药物。抗疟药物氯喹（CHL）及其更安全的衍生物羟氯喹（HCHL）已被提议重新用于治疗 SARS 冠状病毒-2（SARS-CoV-2），这是 COVID-19 的致病因子。CHL/HCHL 具有抗炎活性，用于治疗类风湿性关节炎、骨关节炎和狼疮。虽然 CHL/HCHL 在细胞培养物中对几种病毒具有抗病毒活性，但体内的抗病毒活性尚不确定。重新利用 CHL/HCHL 治疗 SARS-CoV-2 感染很有吸引力。然而，来自其他病毒的动物研究的经验证据表明，CHL/HCHL 可能具有意想不到的矛盾作用。因此，不能排除 CHL 可能会使疾病加重，并对患者和公共卫生努力控制 SARS-CoV-2 的高传染性和爆炸性传播造成有害影响。
相似文献
1
Chloroquine paradox may cause more damage than help fight COVID-19.氯喹悖论可能弊大于利，不利于抗击 COVID-19。
Microbes Infect. 2020 May-Jun;22(4-5):154-156. doi: 10.1016/j.micinf.2020.04.004. Epub 2020 Apr 17.
2
COVID-19 and Antimalarial Drugs: Harms Outweigh Benefits.新型冠状病毒肺炎与抗疟药物：弊大于利
Am J Crit Care. 2020 Nov 1;29(6):489-492. doi: 10.4037/ajcc2020694.
3
A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).呼吁开展随机对照试验以测试氯喹和羟氯喹作为治疗新型冠状病毒病（COVID-19）药物的疗效
Am J Trop Med Hyg. 2020 May;102(5):932-933. doi: 10.4269/ajtmh.20-0230.
4
Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.用于治疗新冠肺炎的氯喹/羟氯喹引发室性心律失常的风险：是否应该使用该药？
Indian Heart J. 2020 Mar-Apr;72(2):131-132. doi: 10.1016/j.ihj.2020.04.006. Epub 2020 Apr 27.
5
Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.氯喹和羟氯喹在2019冠状病毒病中的应用及其心血管影响：理解安全性差异以改进临床试验的解读与设计
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008688. doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.
6
Regulators split on antimalarials for COVID-19.监管机构在用于治疗新冠肺炎的抗疟疾药物问题上存在分歧。
Lancet. 2020 Apr 11;395(10231):1179. doi: 10.1016/S0140-6736(20)30817-5.
7
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.COVID-19、氯喹再利用和心脏安全问题：手性或许有帮助。
Molecules. 2020 Apr 16;25(8):1834. doi: 10.3390/molecules25081834.
8
Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.免疫调节作为 SARS-CoV-2 爆发期间的一种治疗选择：抗疟氨基喹啉的案例。
Front Immunol. 2020 Aug 28;11:2159. doi: 10.3389/fimmu.2020.02159. eCollection 2020.
9
Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.氯喹和羟氯喹在疟疾治疗中的应用和在 COVID-19 治疗中的再利用。
Pharmacol Ther. 2020 Dec;216:107672. doi: 10.1016/j.pharmthera.2020.107672. Epub 2020 Sep 8.
10
The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?4-氨基喹啉类药物（氯喹/羟氯喹）抗 SARS-CoV-2 感染（COVID-19）的可能作用机制：铁稳态的作用？
Pharmacol Res. 2020 Aug;158:104904. doi: 10.1016/j.phrs.2020.104904. Epub 2020 May 13.
引用本文的文献
1
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.伊维菌素、氯喹/羟氯喹及阿奇霉素治疗新冠肺炎的疗效：III期临床试验的系统评价
Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206.
2
Understanding the psychiatric symptoms of COVID-19: a meta-analysis of studies assessing psychiatric symptoms in Chinese patients with and survivors of COVID-19 and SARS by using the Symptom Checklist-90-Revised.理解 COVID-19 的精神症状：使用症状清单 90-修订版评估患有 COVID-19 和 SARS 的中国患者和幸存者的精神症状的研究的荟萃分析。
Transl Psychiatry. 2021 May 17;11(1):290. doi: 10.1038/s41398-021-01416-5.
3
Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.潜在的抗冠状病毒药物及其药理学机制。
Drug Des Devel Ther. 2021 Mar 17;15:1213-1223. doi: 10.2147/DDDT.S293216. eCollection 2021.
4
Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients.氯喹和洛匹那韦/利托那韦对 COVID-19 治疗无效，联合使用会加重病情：重症患者的单中心经验。
Biomed Res Int. 2021 Feb 6;2021:8821318. doi: 10.1155/2021/8821318. eCollection 2021.
5
The find of COVID-19 vaccine: Challenges and opportunities.COVID-19 疫苗的发现：挑战与机遇。
J Infect Public Health. 2021 Mar;14(3):389-416. doi: 10.1016/j.jiph.2020.12.025. Epub 2020 Dec 30.
6
Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.针对严重急性呼吸综合征冠状病毒2感染引发新型冠状病毒肺炎大流行的抗病毒药物。
Tzu Chi Med J. 2020 Aug 25;33(1):7-12. doi: 10.4103/tcmj.tcmj_100_20. eCollection 2021 Jan-Mar.
7
Medicines and illusions in the fight against COVID-19 in Brazil.巴西抗击新冠疫情中的药物与幻想
Ethics Med Public Health. 2021 Mar;16:100622. doi: 10.1016/j.jemep.2020.100622. Epub 2021 Jan 1.
8
Molecular mechanisms and pharmacological interventions in the replication cycle of human coronaviruses.人类冠状病毒复制周期中的分子机制及药理学干预措施。
Genet Mol Biol. 2020 Nov 23;44(1 Suppl 1):e20200212. doi: 10.1590/1678-4685-GMB-2020-0212. eCollection 2020.
9
A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.瑞德西韦与其他抗 SARS-CoV-2 再利用抗病毒药物的比较分析。
EMBO Mol Med. 2021 Jan 11;13(1):e13105. doi: 10.15252/emmm.202013105. Epub 2020 Nov 3.
10
COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor.COVID-19：褪黑素作为 SARS-CoV-2 主要蛋白酶抑制剂的治疗潜力的合理发现。
Int J Med Sci. 2020 Jul 30;17(14):2133-2146. doi: 10.7150/ijms.48053. eCollection 2020.
本文引用的文献
1
[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].羟氯喹治疗中度新型冠状病毒肺炎患者的一项试点研究
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219. doi: 10.3785/j.issn.1008-9292.2020.03.03.
2
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study.羟氯喹和阿奇霉素联合治疗至少随访 6 天的 80 例 COVID-19 患者的临床和微生物学效果：一项前瞻性观察研究。
Travel Med Infect Dis. 2020 Mar-Apr;34:101663. doi: 10.1016/j.tmaid.2020.101663. Epub 2020 Apr 11.
3
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
4
Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?氯喹/羟氯喹在2019冠状病毒病（COVID-19）治疗中会有害吗？
Clin Infect Dis. 2020 Jul 28;71(15):888-889. doi: 10.1093/cid/ciaa321.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
6
Of chloroquine and COVID-19.关于氯喹和 COVID-19。
Antiviral Res. 2020 May;177:104762. doi: 10.1016/j.antiviral.2020.104762. Epub 2020 Mar 5.
7
Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.单次服用他非诺喹预防间日疟原虫疟疾复发的疗效：一项更新的荟萃分析。
Travel Med Infect Dis. 2020 Jul-Aug;36:101576. doi: 10.1016/j.tmaid.2020.101576. Epub 2020 Feb 6.
8
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
9
Stimulation of Innate Immunity by Host and Viral RNAs.宿主和病毒 RNA 对固有免疫的刺激作用。
Trends Immunol. 2019 Dec;40(12):1134-1148. doi: 10.1016/j.it.2019.10.009. Epub 2019 Nov 14.
10
Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya Virus Infection.氯喹治疗增强基孔肯雅热病毒感染的矛盾效应。
Viruses. 2018 May 17;10(5):268. doi: 10.3390/v10050268.
Zotero 插件